Drug
Scaav8otc
Scaav8otc: highest development phase Phase 1/2, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| scAAV8OTC NCT02991144 | Phase 1/2 | Ornithine Transcarbamylase (OTC) Deficiency |
Latest
No recent events.
Follow Scaav8otc on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.